Symbols

PRTA

Prothena·NASDAQ

--(--)

PRTA Profile

Prothena Corporation Plc

A late-stage clinical biotechnology company that develops therapeutics for AL and AA forms of amyloidosis, Parkinson's disease and inflammatory diseases

Industry

Biological Technology

Established Date

09/26/2012

Listing Date

12/21/2012

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.prothena.com

Security Type

Common stock

Office address

77 Sir John Rogerson’s Quay, Block C, Grand Canal Docklands, Dublin 2, D02 VK60, Ireland

Business

Introduction

Prothena Corporation plc was incorporated under the laws of Ireland on 26 September 2012 and re-registered as an Irish public limited company on 25 October 2012. The company is a late-stage clinical biotechnology company with expertise in protein disorders and a range of investigational therapies that have the potential to alter the course of disruptive neurodegenerative diseases and rare peripheral amyloid diseases. The company's wholly-owned projects include birtamimab for the potential treatment of AL amyloidosis, and a series of projects for the potential treatment of Alzheimer's disease, including PRX012 for β-amyloid (Aβ) and the new Aβ-tau dual vaccine PRX123.